Regards drug reimbursements made to 340B covered entities

SB 269 prohibits drug manufacturers and wholesalers from denying, restricting, or discriminating against 340B covered entities when they attempt to acquire discounted drugs. The bill also bans these entities from requiring utilization data as a condition for purchasing these drugs unless such data sharing is already mandated by federal law. Violations of these rules are classified as unlawful practices, allowing the attorney general to impose civil penalties of up to $50,000 per package and refer complaints to the state board of pharmacy for further sanctions. This legislation aims to ensure that specific healthcare organizations can access reduced-price medications without facing additional barriers or data requirements from suppliers.